OBJECTIVE： To investigate the situation of pharmacoeconomic researches about lipid-lowering drugs in China， and to seek the regimen with good cost-effectiveness in order to provide reference for rational drug use in the clinic. METHODS： Retrieved from CNKI and Wanfang database， pharmacoeconomic literatures about lipid-lowering drugs， published in domestic journals during 2011-2015， were included to discuss the problems of pharmacoeconomic researches about lipid-lowering drugs and put forward related suggestions. RESULTS： Rosuvastatin and other medicines showed good cost-effectiveness， while there were many problems of domestic published pharmacoeconomic researches about lipid-lowering drugs， such as different research methods， different treatment courses， different methods of cost calculation， single effect index and absence of ADR. On the whole， the researches were low in quality， which led the difficulty of accurately obtaining the drugs with best cost-effectiveness. CONCLUSIONS： In the future， related researches should confirm research duration and health output index， effect index and evaluation method according to disease types and research objectives； enhance the unity of research and design methods； pay attention to cost discount； in addition， strengthen pharmacoeconomic researches about lipid-lowering TCM and compare it with chemical drugs.